About the event
Commercial biopharmaceutical manufacturing
Commercial biopharmaceutical manufacturing has evolved toward an established and mature state. The increasing demand for monoclonal antibodies drove efforts in the development of high performing bioprocesses at large scale.The advent of biosimilars, the increasing competition, the personalized treatments, the health care costs and the requirements by regulators are challenging the established concepts. These challenges are currently driving the further development of the facilities, the design of new manufacturing concepts that maximize yield and flexibility by minimizing lead times, footprint and capital investment.